Skip to content
The Policy VaultThe Policy Vault

Xifaxan (rifaximin) — Point32Health

Irritable bowel syndrome with diarrhea (IBS-D)

Initial criteria

  • The patient has a documented diagnosis of irritable bowel syndrome with diarrhea (IBS-D)

Reauthorization criteria

  • Documentation of a recurrence of IBS-D symptoms
  • Documentation of a positive clinical response to therapy

Approval duration

14 days per treatment cycle, up to 3 cycles total